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Abstract
Transforming growth factor (TGF)-β signaling is increasingly recognized as a key driver in cancer. In progressive cancer
tissues, TGF-β promotes tumor formation, and its increased expression often correlates with cancer malignancy. In this
study, we utilized adenoviruses expressing short hairpin RNAs against TGF-β1 and TGF-β2 to investigate the role of
TGF-β downregulation in cancer cell death. We found that the downregulation of TGF-β increased the
phosphorylation of several SAPKs, such as p38 and JNK. Moreover, reactive oxygen species (ROS) production was also
increased by TGF-β downregulation, which triggered Akt inactivation and NOX4 increase-derived ROS in a cancer cell-
type-specific manner. We also revealed the possibility of substantial gene fluctuation in response to TGF-β
downregulation related to SAPKs. The expression levels of Trx and GSTM1, which encode inhibitory proteins that bind
to ASK1, were reduced, likely a result of the altered translocation of Smad complex proteins rather than from ROS
production. Instead, both ROS and ROS-mediated ER stress were responsible for the decrease in interactions between
ASK1 and Trx or GSTM1. Through these pathways, ASK1 was activated and induced cytotoxic tumor cell death via p38/
JNK activation and (or) induction of ER stress.
Introduction
The transforming growth factor (TGF) superfamily
comprises three isoforms of multifunctional cytokines
(namely, β1, β2, and β3) that regulate numerous cellular
and biological functions, including cell proliferation,
apoptosis, differentiation, and migration; embryonic pat-
terning; stem cell maintenance; immune regulation; bone
formation; and tissue remodeling and repair1–3. The wide
variety of TGF-β functions is highly cell-type specific and
context dependent1,4. For example, TGF-β acts as a tumor
suppressor in normal and early cancer cells by promoting
apoptosis over proliferation, thus hindering
immortalization5. On the other hand, it also promotes
tumor metastasis by stimulating the
epithelial–mesenchymal transition, chemoattraction,
migration, invasion, and cell adhesion6–10. The mechan-
isms by which TGF-β inhibits cell proliferation while
promoting cell growth and enhancing both stem cell
pluripotency and differentiation remain an enigma11–13.
TGF-β binds to two types of serine/threonine kinase
receptors14, type I and type II, which form heteromeric
cell surface complexes that stimulate the canonical
(Smad-dependent) signaling pathway10. Activation of type
I receptors leads to C-terminal phosphorylation of Smad2
and Smad3, which then dissociate and form a hetero-
trimeric complex with Smad415,16. This complex then
translocates to the nucleus to regulate target gene
expression17,18. TGF-β can also stimulate Smad-
independent signaling pathways, which involve the acti-
vation of small GTP-binding protein Rho19,
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phosphatidylinositol 3-kinase (PI3K)-Akt20–22, and TGF-
β-activated kinase 1 (TAK1)23, as well as Ras-extracellular
signal–regulated kinase (ERK), c-Jun N-terminal kinase
(JNK), and p38 stress-activated protein kinase (SAPK)24–
26.
JNK and p38 are also activated by apoptosis signal-
regulating kinase 1 (ASK1), a mitogen-activated protein
kinase (MAPK) kinase kinase27,28. However, the roles of
JNK and p38 signaling pathways during apoptosis have
been controversial depending on the duration or strength
of the signals29,30. The activation of ASK1 is mainly trig-
gered under cytotoxic stresses by the tumor necrosis
factor Fas and reactive oxygen species (ROS)28,31–33.
ROS are formed as a natural by-product of oxygen
metabolism34. Large amounts of ROS are produced via
multiple mechanisms, depending on the cell and tissue
type35. Elevated levels of ROS have been detected in
almost all cancers, in which they promote many aspects of
tumor development and progression36. However, ROS
can induce cancer cell apoptosis as well as senescence36.
Additionally, low doses of hydrogen peroxide and super-
oxide have been shown to stimulate cell proliferation in a
wide variety of cancer cell types37. Recently, it was shown
that ROS can trigger endoplasmic reticulum (ER) stress or
vice versa in vivo and in vitro38,39. Under prolonged and
severe ER stress, the unfolded protein response (UPR) can
become cytotoxic. Among the UPR signaling pathways,
inositol-requiring enzyme 1α (IRE1α) and protein kinase
RNA-like kinase (PERK) are predominantly represented
as sensors of ER stress40,41. Likewise, oxidative stress-
sensing redox proteins such as thioredoxin (Trx) play a
role in many important biological processes, including
redox signaling42. Trx has antiapoptotic effects, including
a direct inhibitory interaction with ASK143. The redox
state-dependent association and dissociation of Trx with
ASK1 lead to MAPK activation-induced apoptosis44. The
activity of ASK1 is also suppressed by glutathione S-
transferase Mu 1 (GSTM1), an enzyme involved in the
metabolism of drugs and xenobiotics45. Similar to Trx,
GSTM1 protects cells from a variety of stresses, including
oxidative stress45.
In this study, we designed adenoviruses to deliver short
hairpin RNAs (shRNAs) for TGF-β1 or TGF-β2 and
found that downregulation of TGF-β1 or TGF-β2 leads to
tumor cell death by inducing ASK1 activation and p38
and JNK phosphorylation through an ER stress/ROS-
escalated positive feedback circuit.
Materials and methods
Cell culture
Human A549 (lung adenocarcinoma), U251N (glio-
blastoma), DU-145 (prostate cancer), Huh-7 (hepatocarci-
noma), MDA-MB-231 (breast carcinoma), MDA-MB-231-
Her2 (Her2-stably transfected breast carcinoma), SK-Hep1
(hepatocarcinoma), A375 (melanoma), HPAC (pancreas
adenocarcinoma), MiaPaCa-2 (pancreas adenocarcinoma),
and human embryonic kidney 293A cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM, HyClone,
Logan, UT, USA) containing 10% fetal bovine serum (FBS,
HyClone, Logan, UT, USA). Human normal pancreatic cells
(Applied Biological Materials, Canada) were cultured in
Prigrow II medium containing 10% FBS. Cells were main-
tained in a 37 °C humidified atmosphere containing 5%
CO2.
Reagents
Small interfering RNAs (siRNAs) for NOX4, NOX1,
Smad4, and ASK1 and antibodies against glyceraldehyde
3-phosphate dehydrogenase, phospho-HSP27 (Ser78),
HSP27, Trx, GSTM1, AP1, SP1, Smad4, ASK1, and
phospho-ASK1 (Thr845) were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies
against p38, phospho-p38 (Thr180/Tyr182), phospho-
ERK (Thr202/Tyr204), phospho-src (Tyr416), phospho-
Akt (Ser473), phospho-stat3 (Tyr705), phospho-p65
(Ser536), phospho-JNK (Thr183/Tyr185), phospho-
Smad2 (Ser465/467), phospho-Smad3 (Ser423/425),
Smad2, Smad3, p65, ERK, Akt, stat3, JNK, src, BIP, Cal-
nexin, Ero1-Lα, CHOP, PERK, and PDI were purchased
from Cell Signaling Technology (Beverly, MA, USA).
Phospho-IRE1α was purchased from Thermo Fisher Sci-
entific (Waltham, MA, USA). Peroxiredoxin (Prx) was
purchased from Abfrontier (Seoul, Korea). Glutaredoxin
(Grx) was purchased from Novus Biologicals (Littleton,
CO, USA). Recombinant human TGF-β1 and TGF-β2
were purchased from R&D Systems (Minneapolis, MN,
USA). SB203580 was purchased from EMD Millipore
(Billerica, MA, USA), and GKT137831 was purchased
from ApexBio (Houston, TX, USA). All other chemicals
were purchased from Sigma-Aldrich (St. Louis, MO,
USA).
Construction of shuttle vectors expressing human TGF-β1
and TGF-β2 shRNA
The detailed construction of human TGF-β1 and TGF-
β2 shRNA was described in Oh et al.46. The target
sequence of TGF-β1 (5’-ACCAGAAATACAGCAACAA
TTCCTG-3’) was selected after validation among three
candidate sequences (Suppl. Figure 1A). The target
sequence of TGF-β2 (5’-GGATTGAGCTATATCAGA
TTCTCAA-3’) was selected after validation among five
candidate sequences (Supple. Figure 1B). To express
human TGF-β1 shRNA in adenovirus, the top strand
sequence (5’-GATCCGCCAGAAATACAGCAACAATT
CCTGTCTCTCCAGGAATTGTTGCTGTATTTCTGG
TTTTTTTA-3’) and the bottom strand sequence (5’-A
GCTTAAAAAAACCAGAAA TACAGCAACAATTCC
TGGAGAGACAGGAATTGTTGCTGTATTTCTGG
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TG-3’) were annealed and subcloned into BamHI/Hin-
dIII-digested pSP72ΔE3-U6 E3 shuttle vector to generate
pSP72ΔE3-U6-shTGF-β1. To express human TGF-β2
shRNA in adenovirus, the top strand sequence (5’-G
ATCCGGATTGAGCTATATCAGATTCTCAATCTCT
TGAGAATCTGATATAGCTCAATCCTTTTA-3’) and
the bottom strand sequence (5’- AGCTTAAAAGGA
TTGAGCTATATCAGATTCTCAAGAGATTGAGAAT
CTGATATAGCTCAATCCG-3’) were annealed and
subcloned into BamHI/HindIII-digested pSP72ΔE3-U6
E3 shuttle vector to generate pSP72ΔE3-U6-shTGF-β2.
Production of adenoviral vectors
These vectors, named pSP72ΔE3-U6-shTGF-β1 or
pSP72ΔE3-U6-shTGF-β2, were linearized by XmnI
digestion and co-transformed into Escherichia coli BJ5183
together with the SpeI-digested adenoviral vector (dl324-
IX) for homologous recombination. The recombined
adenoviral plasmids dl324-IX-ΔE3-U6-NC, dl324-IX-
ΔE3-U6-shTGF-β1, and dl324-IX-ΔE3-U6-shTGF-β2
were then digested with PacI and transfected into 293A
cells to generate replication-incompetent adenovirus (Ad-
NC, Ad-shTGF-β1, and Ad-shTGF-β2).
Names of the recombinant adenoviruses
Ad-NC, negative control adenovirus
Ad-shTGF-β1, adenovirus expressing shRNA for
human TGF-β1
Ad-shTGF-β2, adenovirus expressing shRNA for
human TGF-β2
MTS viability assay
The CellTiter 96® Aqueous Assay Kit (Promega, Madi-
son, WI, USA) is composed of solutions of a novel tetra-
zolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt (MTS)) and an electron coupling reagent (phe-
nazine ethosulfate). MTS is bioreduced by cells into a for-
mazan product that is soluble in tissue culture media. After
adenovirus (NC, shT1, shT2) infection at a multiplicity of
infection (MOI) of 100 for 48 h to A375 or HPAC cell lines
in 96-well plates, a total of 50 μL of supernatant from each
well was transferred into a new 96-well flat-bottom plate.
The absorbance of the formazan at 490 nm was measured
directly from 96-well assay plates without additional pro-
cessing. The conversion of MTS into aqueous, soluble
formazan is accomplished by dehydrogenase enzymes
found in metabolically active cells. The quantity of for-
mazan product as measured by the absorbance at 490 nm is
directly proportional to the number of living cells in culture.
Western blot analysis
Cells were lysed with 1× Laemmli lysis buffer (62.5 mM
Tris, pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol,
0.002% bromophenol blue), and the protein concentration
was determined using a BCA Protein Assay Kit (Thermo
Scientific, Fremont, CA, USA). Then protein samples
were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), and the gels were
electro-transferred onto a polyvinylidene difluoride
membrane (Millipore, Billerica, MA, USA). Each mem-
brane was blocked with 5% nonfat dry milk in phosphate-
buffered saline (PBS)-Tween-20 (0.1%, v/v) at room
temperature for 1 h. The membrane was then incubated
with primary antibody (diluted according to the manu-
facturer’s instructions) for 2 h. Horseradish peroxidase-
conjugated anti-rabbit or anti-mouse immunoglobulin G
(IgG) was used as a secondary antibody. Immunoreactive
proteins were visualized with a chemiluminescent detec-
tion kit (ELPIS biotech, Daejon, Korea). For imaging, a
ChemiDoc system (Syngene, Frederick, MD, USA) was
used.
Real-time polymerase chain reaction (RT-PCR)
After infection of adenovirus expressing shRNA for
TGF-β1 or -β2 at an MOI of 100, cells were lysed with
Trizol reagent (Life Technologies, Carlsbad, CA, USA),
and the total RNA was isolated using chloroform. The
RNA concentration was determined using a Nanodrop
2000 (Thermo Scientific). The real-time PCR was per-
formed using a Power SYBR Green RNA-to-CT 1-Step
Kit (Life Technologies). The reaction mixture contained
the reverse transcriptase enzyme mix, reverse transcrip-
tion PCR mix, forward primer, reverse primer, RNA
template, and nuclease-free water. Human TGF-β1 cDNA
was amplified using the forward primer 5’-T
TGCTTCAGCTCCACAGAGA-3’ and the reverse primer
5’-TGGTTGTAGAGGGCAAGGAC-3’. Human TGF-β2
cDNA was amplified using the forward primer 5’-G
TGAATGGCTCTCCTTCGAC-3’ and the reverse primer
5’-CCTCGAGCTCTTCGCTTTTA-3’. Human NOX4
cDNA was amplified using the forward primer 5’- A
GGAGAACCAGGAGATTGTTGGATAAA-3’ and the
reverse primer 5’- ATCTGAGGGATGACTTATGACCG
AAAT-3’. Human β-actin was amplified using the forward
primer 5’-GGCTGTATTCCCCTCCATCG-3’ and the
reverse primer 5’-CCAGTTGGTAACAATGCCATGT-3’.
Microarray analyses
cDNA microarray was performed using total RNA iso-
lated from two different cancer cell lines after 48 h of
infection with TGF-β1 or -β2 shRNA-expressing adeno-
virus. RNA was prepared using Trizol (Invitrogen Life-
Technologies). All cDNA microarray experiments,
including cRNA labeling, hybridization to the Illumina
expression bead-chip, scanning, and data analyses using
Illumina GenomeStudiov2011.1, were performed by
Macrogen Inc. (Seoul, Korea).
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Clonogenic assay
For survival determination, cells were plated on 6-well
plates at 1 × 105 cells/well. After adenovirus (NC, shT1,
shT2) infection at an MOI of 100 for 48 h in A375 or
HPAC cell lines, cells were trypsinized and replated in the
wells of 6-well plates at 5 × 103 or 1 × 104 cells/well. Then
the cells were monitored daily by microscopy. When cells
formed colonies, the remaining cells on the plate were
fixed with 4% paraformaldehyde and stained with 0.5%
crystal violet.
Measurement of intracellular levels of ROS
Intracellular ROS were assessed using the ROS-specific
probe 2’-7’-diclorofluorescein diacetate (DCF-DA, Sigma-
Aldrich, St. Louis, MO, USA). Cells were incubated with
20 μM DCF-DA for 1 h, and fluorescence signals were
obtained with a fluorescence microscope (Olympus IX71).
Enzyme-linked immunosorbent assay (ELISA)
Cells were plated in the wells of 6-well plates at 1 × 105
cells/well. After 48 h, the supernatants were collected. The
levels of secreted TGF-β1 or TGF-β2 were determined by
ELISA according to the manufacturer’s instructions (R&D
Systems, Minneapolis, MN, USA).
Site-directed mutagenesis
HA-tagged ASK1 wild type was constructed in the
pCDNA3.1 plasmid (Invitrogen, Carlsbad, CA). A kinase-
inactive form of ASK1 (K709M) was constructed from
PCR using pcDNA3.1-HA-ASK1 as a template and the
QuickChange II Site-Directed Mutagenesis Kit (Agilent
Technologies, Santa Clara, SF, USA). The sense and
antisense primers used were 5′-GCAACCAAGTCA-
GAATTGCTATTATGGAAATCCCAGAGAGAGAC-3′
and 5′-GTCTCTCTCTGGGATTTCCATAATAGCAAT
TCTGACTTGGTTGC-3′, respectively, for K709M.
Immunoprecipitation (IP)
Co-IP procedures were performed at 4 °C unless
otherwise indicated, using a Pierce spin column that can
be capped and plugged with a bottom plug for incubation
or unplugged to remove the supernatant by centrifugation
at 1000 × g for 1 min. Binding of Trx, GSTM1, ASK1,
AP1, SP1, or Smad4 antibody to protein A/G agarose was
performed using the protocol described in Pierce cross-
link IP kits with slight modification. Protein A/G agarose
slurry (20 µl) was washed twice with 200 µl of PBS buffer
and incubated with 100 µl of Trx, GSTM1, ASK1, AP1,
SP1, or Smad4 antibody prepared in PBS (10 µl of Trx,
GSTM1, ASK1, AP1, SP1, or Smad4 antibody+ 85 µl of
H2O+ 5 µl of 20× PBS) at 25 °C for 30min on a mixer. In
parallel, mouse or rabbit serum with the same con-
centration of IgG was similarly prepared as a negative
control (NC). Then the supernatant was discarded, and
the beads were washed three times with 300 µl of PBS,
followed by incubation with 50 µl of disuccinimidyl
suberate (DSS) solution (2.5 µl of 20× PBS+ 38.5 µl of
H2O+ 2.5 mM DSS in dimethyl sulfoxide) at 25 °C for
45–60 min on a mixer. After removing the supernatant,
the beads were washed three times with 50 µl of 100mM
glycine (pH 2.8), twice with 300 µl of PBS buffer con-
taining 1% NP-40 and then once with 300 µl of PBS. The
antibody-crosslinked beads were incubated overnight at 4
°C with 600 µl of lysate of A375 or HPAC cells that was
pre-cleared with control agarose resin (Pierce) for 1 h on a
shaker. After removing the supernatant (flow-through)
and washing with 300 µl of washing buffer (25 mM Tris,
150mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol, pH
7.4) three times, the immunoprecipitates were eluted with
60 µl of elution buffer and then boiled for 10 min. The
eluted complex was subjected to SDS-PAGE separation
for western blotting.
Chromatin IP assay (ChIP assay)
The ChIP assay was performed using a kit from Thermo
Scientific (Thermo Fisher Scientific, Waltham, USA)
according to the manufacturer’s instructions. Briefly, fol-
lowing treatment, cells were washed with PBS, crosslinked
with 1% formaldehyde for 10min, rinsed with ice-cold
PBS, collected into PBS containing protease inhibitors,
and then resuspended in lysis buffer (1% SDS, 10 mM
EDTA, 50mM Tris at pH 8.1 with 1% protease inhibitor
cocktail). After the cells were sonicated to produce
200–1000-bp DNA fragments, followed by centrifugation
to remove insoluble material, IP was performed with the
indicated antibodies overnight at 4 °C with mixing. Then
20 μL of protein A/G beads was added to each IP and
incubated for 2 h at 4 °C with mixing. After removing the
supernatant, the beads were washed twice with IP Wash
Buffer 1, once with Wash Buffer 2, once with 150 μL of 1×
IP Elution Buffer, and then incubated at 65 °C for 30 min
with vigorous shaking. After dispensing the supernatant
(containing the eluted protein–chromatin complex) into
prepared tubes with NaCl and Proteinase K in a 65 °C heat
block for 1.5 h, 750 μL of DNA Binding Buffer was added,
and 500 μL of each sample was removed into a DNA
Clean-Up Column, which was inserted into a 2 mL col-
lection tube. After removing the supernatant (flow-
through), the remaining sample was dispensed into the
same DNA Clean-Up Column and washed once with
Wash Buffer, and 50 μL of DNA Column Elution Solution
was added to the column. After centrifugation, the
resulting solution was the purified DNA. RT-PCR was
performed using primers specific for the human Trx
promoter (5’-TCCAGGAGTCTGCCTCTGTTAG-3’ and
5’-CTGCTGGA GTCTGACGAGCG-3’) and the GSTM1
promoter (5’-TAGGATCTGGCTGGTGTCTC-3’ and 5’-
GTGCGGATTCCGCAGACAGG-3’). PCR using
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Absolute qPCR SYBR Green Fluorescein Mix (Thermo
Scientific) was performed as follows: 40 cycles of 95 °C for
15 s and 62 °C for 1 min, with an initial incubation at 95 °C
for 15min.
Confocal immunofluorescence staining
Cells were fixed with 4% formaldehyde for 15min and
then washed three times with PBS. After washing with
PBS 3 times, the slides were incubated with 5% bovine
serum albumin (BSA) for 1 h. After blocking, the slides
were incubated in primary antibody (Smad4) at the
appropriate dilution (1:100) in PBS for 12 h at 4 °C and
then washed three times with PBS. After washing with
PBS 3 times, the slides were incubated in Flamma 552-
conjugated secondary antibody (1:1000) (BioActs, Korea)
in PBS for 1 h at room temperature and then washed three
times with PBS. After washing with PBS 3 times, the slides
were counterstained with DAPI-Fluoromount-G (Aviva,
San Diego, USA) for 20min at room temperature to stain
nuclei and then coverslipped. Images were acquired using
a confocal laser scanning microscope (Carl Zeiss, Jena,
Germany).
Nucleus/cytosol fractionation
Cells were lysed with 0.5% Triton X-100 lysis buffer (50
mM Tris-HCI (pH 7.5), 0.5% Triton X-100, 137.5 mM
NaCI, 10% glycerol, 1 mM sodium vanadate, 5 mM
EDTA, and protease inhibitors (1 mM phenylmethane-
sulfonylfluoride)) on ice for 15min and then centrifuged
at 3000 rpm for 5 min. After centrifugation, the super-
natant (membrane/cytoplasmic fraction) was transferred
into a new microcentrifuge tube, and the nuclear pellets
were rinsed with lysis buffer and centrifuged at 13,000
rpm for 15min. After centrifugation, the supernatants
were transferred into a new microcentrifuge tube, and
then an equal amount of 2× SDS-PAGE sample buffer was
added to the tubes containing the nuclear and membrane/
cytoplasmic fractions. Both tubes were boiled for 10min,
and each boiled sample was subjected to SDS-PAGE
separation for western blotting.
Animal study
To generate a xenograft tumor model, 8 × 106 A375 or
HPAC cells were injected into the subcutaneous abdom-
inal region of male BALB/c athymic nude mice. When the
tumors reached an average size of 60–80mm3, the nude
mice received intratumoral injections of 1 × 109 plaque-
forming units (pfu) of oncolytic adenovirus diluted in 50
μL of PBS or PBS alone. The adenoviruses used were
defective control adenovirus (Ad-shNC) and TGF-β1 or
TGF-β2 shRNA-expressing defective adenoviruses (Ad-sh
TGF-β1, Ad-shTGF-β2). Intratumoral injection was
repeated three times every other day. Regression of tumor
growth was assessed by taking measurements of the
length (L) and width (W) of the tumor. Tumor volume
was calculated using the following formula: volume=
0.52 × L ×W2.
Immunohistochemistry (IHC)
For IHC, tumor tissues were extracted, fixed for 24 h in
10% formaldehyde, and embedded in paraffin. IHC
staining was performed as follows. Tissue sections were
deparaffinized twice with xylene for 10min and were
rehydrated using a graded alcohol series. After removing
endogenous peroxidases using 0.1% H2O2, sections were
washed three times with PBS. Antigen retrieval was
achieved by incubating the sections in 10mM citrate
buffer (pH 6.0) (DAKO, Glostrup, Denmark) using a
microwave oven. Then the sections were permeabilized
with 0.5% PBX (0.5% Triton X-100 in PBS) for 30 min and
washed three times with PBS. After blocking for 1 h with
5% BSA, the primary antibody was added, and the sections
were incubated overnight at 4 °C. Primary Antibody
Enhancer (Thermo Fisher Scientific, Waltham, MA, USA)
and horseradish peroxidase Polymer (Thermo Scientific)
were used for signal amplification. To develop the colored
product, a mixture of DAB (3,3′-diaminobenzidine) Plus
Chromogen and DAB Plus Substrate (Thermo Fisher
Scientific) was added for 5 min. After washing with PBS,
20% hematoxylin counterstain was added for 2–5min to
stain the nuclei. Finally, the tissue sections were dehy-
drated in a graded alcohol series. After clearing twice in
xylene, the tissue sections were coverslipped with
mounting media (xylene:mount= 1:1) for microscopy.
TUNEL assay
To measure in situ apoptosis, a terminal deox-
ynucleotidyl transferase-mediated dUTP nick end labeling
(TUNEL) assay was performed using tumor tissue sec-
tions prepared as described for IHC. The TUNEL assay
was carried out according to the manufacturer’s instruc-
tions (Promega, Madison, WI, USA).
Statistical analysis
The data are expressed as the mean ± standard error
(SE). Differences between groups were examined using
unpaired two-tailed t tests. Statistical comparison was
made using the Graph Pad (Systat Software Inc.). p Values
<0.05 were considered statistically significant (*p < 0.05;
**p < 0.01).
Results
Downregulation of TGF-β1 and TGF-β2 after infection with
adenoviruses expressing shRNAs of TGF-β
Almost all human tumors overexpress TGF-β, primarily
TGF-β1 and TGF-β2, which contribute to the induction
of tumor cell invasion and metastasis47. To decrease the
expression of TGF-β1 and TGF-β2, we infected human
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melanoma (A375) or pancreatic cancer (HPAC) cells with
recombinant adenoviruses containing shRNA for TGF-β1
or TGF-β2 (shTGF-β1 or shTGF-β2, respectively) at
various MOIs (10, 50, and 100). The shRNA sequences
used in the experiment after screening several candidate
target sequences originated from Oh et al.46 (Suppl. Fig-
ure 1A, B). The mRNA and protein levels of TGF-β1 and
TGF-β2 were measured by real-time PCR and ELISA,
respectively. The results show that TGF-β1 mRNA levels
were suppressed by 80% at an MOI of 100, at which TGF-
β2 mRNA levels were suppressed by 75% (Fig. 1a, b).
Similarly, the protein levels of TGF-β1 and TGF-β2 were
also reduced (Fig. 1a, c).
shTGF-β1 and shTGF-β2 induce the phosphorylation of
SAPKs
Because high expression of TGF-β is correlated with
malignancy in many cancers3, we investigated the effect of
TGF-β downregulation in cancer cell lines. We first
examined whether shTGF-β1 or shTGF-β2 could inhibit
cancer cell survival using a clonogenic assay, which can
measure long-term cancer cell survival. The results of the
clonogenic assay revealed that the survival of various
cancer cells was reduced after infection with adenoviruses
carrying shTGF-β1 or shTGF-β2 (Fig. 1b). To examine
the impact of TGF-β downregulation on the overall gene
fluctuation, a global transcriptomic response was assessed
by microarray. Figure 1c shows clearly different patterns
of z scores after clustering analysis between control cells
(A375 and HPAC cells) and TGF-β-downregulated con-
trol cells, suggesting a possibility of substantial gene
fluctuation toward cell death after TGF-β downregulation
(Supple. Figure 2). To further demonstrate that cell death
by TGF-β downregulation is also caused by SAPK path-
ways, we examined various key signaling molecules of
SAPK pathways. We observed that the levels of
phosphorylated-p38 (phospho-p38), phosphorylated-
HSP27 (phospho-HSP27), phosphorylated-JNK (phos-
pho-JNK), and phosphorylated-ERK (phospho-ERK) were
increased by shTGF-β1 and shTGF-β2 (Fig. 1d). However,
after TGF-β downregulation in normal pancreatic cells,
the phosphorylation levels of various key signaling path-
way molecules, including HSP27, JNK, and ERK, did not
change (Fig. 1e). To determine whether shTGF-β1 or
shTGF-β2 produced off-target effects, we analyzed A375
cells infected with adenoviruses carrying the shRNAs and
supplemented the cells with recombinant TGF-β protein.
Western blot analyses showed that the addition of
recombinant TGF-β1 protein restored the levels of
phospho-src, phospho-p65, phospho-stat3, phospho-
HSP27, and phospho-p38 (Suppl. Figure 3A). Addition-
ally, morphological recovery was also observed (Suppl.
Figure 3B). Similar patterns were also observed with
recombinant TGF-β2 protein (Suppl. Figure 3C, D),
suggesting that there were no off-target effects of shTGF-
β1 or shTGF-β2. Then we investigated whether TGF-β
itself could also activate p38 in the cancer cells in which
TGF-β downregulation activated p38. Supplementary
figure 4 shows the weak activation of p38 in cancer cells
and specific survival molecules, for example, p65 in A375
cells or Akt and stat3 in HPAC cells, after TGF-β1
treatment with no complete sign of cell death.
shTGF-β1 and shTGF-β2 induce ROS generation in cancer
cells
ROS are known to be related to JNK and p38 pathway
activation48–50. Thus we assessed the generation of ROS
in A375 and HPAC cells infected with adenoviruses car-
rying shRNAs for TGF-β1 and TGF-β2. We found that
knockdown of TGF-β1 greatly stimulated the generation
of ROS in A375 cells 48 h after adenovirus infection. In
contrast, few ROS were generated in A375 cells after
knockdown of TGF-β2 or in HPAC cells after knockdown
of TGF-β1 or TGF-β2, and ROS were barely detectable in
normal pancreatic cells after TGF-β downregulation
(Fig. 1f), which was primarily derived from low infection
efficiency in normal pancreatic cells (data not shown). N-
acetylcysteine (NAC) is an aminothiol and a synthetic
precursor of intracellular cysteine and glutathione and is
thus considered a strong antioxidant51. Because shTGF-
β1 induced ROS in A375 cancer cells, we next evaluated
the effect of NAC on cell growth and apoptosis. We found
that, as predicted, NAC treatment reduced ROS levels in
A375 cells. (Fig. 1g). Furthermore, cell death was inhibited
(Fig. 1g, h), suggesting that ROS production was respon-
sible for the cancer cell death induced by TGF-β1
downregulation; however, cell death still occurred with-
out much ROS generation in HPAC cells (Fig. 1g, h).
NOX4 is responsible for ROS generation induced by the
downregulation of TGF-β
Next, we examined various ROS-generating enzymes,
including NOX1, NOX4, and 5-lipoxygenase. Nicotina-
mide adenine dinucleotide phosphate oxidase is one of the
main sources implicated in the production of cellular
ROS52,53. Among the ROS-generating enzymes, NOX4
was strongly expressed after TGF-β1 downregulation but
not after TGF-β2 downregulation (Fig. 2a), and its
expression induced by TGF-β1 downregulation was
almost completely repressed by constitutive Akt activa-
tion in A375 cells (Fig. 2b). However, NOX4 was not
detected in HPAC cells. Figure 2c shows that NOX4
mRNA levels in HPAC cells, compared with those in
A375 cells, were barely detectable. Intriguingly, NOX4
expression was also repressed by ROS inhibition or p38
inhibition, which are downstream molecules of NOX4
(Fig. 2d–f), suggesting that a positive feedback loop was
formed to sustain cancer cell death in A375 cells.
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However, the Smad signaling pathway was not involved in
NOX4 generation (Fig. 2f, g). To demonstrate NOX4
function as an indispensable part of TGF-β1 down-
regulation-induced cancer cell death in A375 cells, both
NOX4 siRNA and GKT137831 (ApexBio, Houston, TX,
USA) as a NOX4 inhibitor were used to determine whe-
ther its inhibition could reverse TGF-β1 downregulation-
induced ROS generation/ER stress and subsequent cancer
cell death. Figure 2h, i demonstrated that NOX4 was an
essential mediator of TGF-β1 downregulation-induced
cancer cell death in A375 cells. However, owing to the
nature of dual NOX1/NOX4 inhibition of GKT137831,
NOX1 siRNA was also used to check the possibility of
NOX1 involvement in TGF-β1 downregulation-induced
ROS generation/ER stress and subsequent cancer cell
death. As a result, NOX1 was not found to be involved in
this pathway (Fig. 2j).
ASK1 functions as a key mediator of TGF-β1
downregulation-induced cell death
As ASK1 and SAPKs were activated during TGF-β1
downregulation-induced apoptosis in A375 and HPAC
cells, we investigated whether the ASK1 signaling cascade
was the main regulator of this pathway. As shown in
Fig. 3, downregulation of ASK1 using ASK1 siRNA
restored the viability (Fig. 3a) and morphology (Fig. 3b) of
cells following TGF-β downregulation. Furthermore,
ASK1 siRNA also reversed SAPK activation, including
ASK1 activation. Interestingly, survival signals including
Akt, src, or stat3 activation and Trx/GSTM1 showed
nearly no recovery (Fig. 3c). To confirm that ASK1 acti-
vation drives cell death following TGF-β downregulation,
we constructed and utilized an inactive ASK1 mutant,
ASK1 (K709M). Similar results were also obtained using
this mutant and ASK1 inhibition using siRNA (Fig. 3d–f).
Non-canonical signaling through Akt inactivation by TGF-β
downregulation triggers ROS–ASK1 axis activation
Then we investigated the source of ROS–ASK1 axis
activation and found that the Smad signaling pathway was
not involved in TGF-β downregulation-induced ROS
generation (Fig. 3g) or ER stress (Fig. 3h). Therefore,
PI3K-Akt, as a well-known non-canonical TGF-β signal-
ing pathway, was investigated to determine whether it was
the main source of ROS generation using a constitutively
active form of Akt, N-terminally myristoylation signal-
attached Akt (myr-Akt). As expected, TGF-β down-
regulation-induced ROS generation was greatly decreased
by Akt activation (Fig. 3i). The decrease in ROS caused by
Akt activation also decreased both ER stress and
(see figure on previous page)
Fig. 1 TGF-β downregulation and ROS generation by TGF-β shRNAs. A Downregulation of TGF-β1 and TGF-β2 after infection with adenoviruses
expressing TGF-β shRNAs. a Schematic structure of adenoviral vectors expressing TGF-β shRNA. dl324-ΔE1A-ΔE1B-ΔE3-IX-U6-NC (Ad-NC) is a
replication-incompetent adenovirus used as the negative control. It contains the scrambled DNA sequence for shRNA, which is under the control of
the U6 promoter. dl324-ΔE1A-ΔE1BΔE3-IX-U6-shTGF-β1 or -β2 (Ad-shTGF-β1 or -β2) is a replication-incompetent adenovirus expressing human TGF-
β1 or -β2 shRNA. NC negative control. b Downregulation of human transforming growth factor β1 (TGF-β1) or β2 by adenovirus expressing shTGF-β1
or -β2. Human A375 and HPAC cells were infected with various MOIs of adenovirus expressing shRNA targeting human TGF-β1 (Ad-shTGF-β1) or
human TGF-β2 (Ad-shTGF-β2) or scrambled RNA (Ad-NC). TGF-β1 or -β2 mRNA was assayed by quantitative real-time polymerase chain reaction
(qRT-PCR), and c protein levels were assayed by enzyme-linked immunosorbent assay (ELISA). MOI multiplicity of infection, NC negative control. Error
bars represent the standard error from three independent experiments. B Various cancer cell lines were treated with adenovirus expressing shTGF-β1
or -β2 for 48 h and incubated for an additional 14 days for clonogenic assays. The numbers indicate the relative ratio of clone numbers to those of
Ad-NC. C Global transcriptome analysis of TGF-β downregulation. Expression values of differentially expressed genes are shown in heat map format.
Gene expression levels are visualized as row standardized z scores ranging from green (−1) to red (+1) across all samples. The rows are organized by
hierarchical clustering analysis with complete linkage and Euclidean distance as a measure of similarity from samples of A375 cells (NC, shTGF-β1,
shTGF-β2) (Left) and HPAC cells (NC, shTGF-β1, shTGF-β2) (Right). NC, A375, and HPAC cells infected with adenovirus expressing nonsense shRNA as a
negative control at 100 MOI; shTGF-β1 or -β2; A375 and HPAC cells infected with adenoviruexpressing TGF-β1 or -β2 shRNA at 100 MOI. D Effect of
adenovirus expressing shTGF-β1 or shTGF-β2 in various cancer cell lines. Each cell line was treated with adenovirus expressing shTGF-β1 or shTGF-β2
at 100 MOI. After 48 h, the expression levels of p-p38, p38, p-HSP27, HSP27, p-ERK, ERK, p-JNK, JNK, and GAPDH were detected via western blot
analysis. E Pancreatic normal cell lines were treated with adenovirus expressing shTGF-β1 or -β2 at 100 MOI. After 48 h, the expression levels of p-p38,
p38, p-HSP27, HSP27, p-ERK, ERK, p-JNK, JNK, and GAPDH were detected via western blot analysis. F ROS generation was induced by shTGF-β1- and
shTGF-β2-expressing adenoviruses. A375 cells, HPAC cancer cells, and pancreatic normal cells were infected with adenovirus expressing shTGF-β1 or
-β2 at 100 MOI, respectively, after 48 h of incubation with DCF-DA (20 μM, 1 h) for the detection of ROS using a fluorescent reader and microscopy.
Cell viability was tested via an MTS viability assay after 48 h of infection. Error bars represent the standard error from three independent experiments.
p Values <0.01 indicate a very significantly different viability of Ad-shTGF-β1 or -β2 compared to the control (Ad-NC). G Effects of NAC treatment with
adenovirus expressing TGF-β1 or -β2 shRNA in melanoma and pancreatic cancer cells. A375 (top) or HPAC (bottom) cells were infected with
adenovirus expressing shTGF-β1 or -β2 at 100 MOI, respectively. After 6 h, infected cells were treated with NAC (10mM) for 42 h and then incubated
with DCF-DA (20 μM, 1 h) for the detection of ROS using a fluorescent reader and microscopy. H A375 and HPAC cells were infected with adenovirus
expressing shTGF-β1 or -β2. After 6 h, infected cells were treated with NAC (10mM) for 42 h, and then the expression levels of PARP, p-ASK1, ASK1, p-
p38, p38, p-JNK, JNK, Trx, and GAPDH were detected by western blot analysis
Han et al. Experimental & Molecular Medicine          (2018) 50:162 Page 8 of 19
Official journal of the Korean Society for Biochemistry and Molecular Biology
Fig. 2 (See legend on next page.)
Han et al. Experimental & Molecular Medicine          (2018) 50:162 Page 9 of 19
Official journal of the Korean Society for Biochemistry and Molecular Biology
ASK1–p38/JNK cascade-induced apoptosis (Fig. 3j–l).
These results support the strong correlation between the
lack of effect on Akt inactivation and the loss of NOX4
expression/trivial ROS production following TGF-β1
downregulation in HPAC cells
TGF-β downregulation decreases Trx and GSTM1
expression and the formation of complexes with ASK1
Next, we investigated how HPAC cells die concomitant
with ASK1 activation and trivial ROS production. We
found that TGF-β downregulation decreased both the
mRNA and protein levels of Trx and GSTM1, both of
which act as negative ASK1-interacting regulators by
inhibiting ASK1 kinase activity and cytotoxicity in both
A375 and HPAC cells (Fig. 4a, b). Moreover, the inter-
actions between Trx and ASK1 and between GSTM1 and
ASK1 were also reduced by TGF-β downregulation, par-
ticularly by TGF-β1 downregulation (Fig. 4c). In contrast,
NAC treatment restored the interactions between Trx
and ASK1 and between GSTM1 and ASK1, which is likely
related to the repression of ROS production (Fig. 4d).
These results strongly suggest that an increase in ASK1
activity follows both reduced Trx and GSTM1 expression
and the dissociation of ASK1–Trx and ASK1–GSTM1
complexes. However, this increased ASK1 activity leads to
HPAC cancer cell death only by reduced Trx and GSTM1
expression.
Regulation of Trx and GSTM1 promoter activity and AP-1,
Sp1, and Smad expression by TGF-β
Because TGF-β downregulation suppressed Trx and
GSTM1 expression, we examined their promoter
sequences to identify the possible mechanism underlying
this finding. The Trx promoter contains several consensus
AP-1 (21) and Sp1 (2) binding sites, whereas the GSTM1
promoter contains AP-1-binding sites (30) but not the
Sp1-binding site, as revealed by the Champion ChiP
transcription factor search program supplied by Qiagen
(Germantown, MD, USA). We found that TGF-β down-
regulation decreased Trx and GSTM1 promoter binding
by Sp1 and Ap1 proteins (Fig. 5a), most likely due to
decreased AP-1 and Sp1 protein levels (Fig. 5b). As
canonical TGF-β signaling primarily regulates gene tran-
scription via Smads54, we investigated the levels of acti-
vated Smad proteins following infection with
adenoviruses expressing shRNAs for TGF-β1 or TGF-β2.
Western blot analysis showed that the expression levels of
phospho-Smad2 and phospho-Smad3 were decreased
(Fig. 5c). In addition, IP results also demonstrated
reduced interactions of AP-1 and Sp1 with Smad proteins
(Fig. 5d), suggesting that the reduction in the Smad
complex, including Smad4, makes it difficult to mobilize
to the nucleus, where these proteins act as transcription
factors. In support of the inability of Smad4 to translocate
to the nucleus during TGF-β downregulation, Smad4
(see figure on previous page)
Fig. 2 NOX4 is responsible for TGF-β downregulation-induced ROS generation. a A375 and HPAC cells were infected with adenovirus
expressing shTGF-β1 or -β2 at 100 MOI, respectively. After 48 h, the expression levels of NOX1, NOX4, 5-lipoxygenase, and GAPDH were detected by
western blot analysis. b A375 and HPAC cells were infected with adenovirus expressing shTGF-β1 or transfected with pCMV6-myr-Akt or infected with
adenovirus expressing shTGF-β1 and subsequently transfected with pCMV6-myr-Akt. After 48 h, NOX4, phospho-Akt, Akt, and GAPDH were detected
by western blot analysis. c Expression levels of NOX4 mRNA in A375 and HPAC cells were assayed by quantitative real-time polymerase chain reaction
(qRT-PCR). d A375 cells were infected with adenovirus expressing shTGF-β1. After 6 h, infected cells were treated with NAC (10 mM) for 42 h, and then
the expression of NOX4 and GAPDH was detected by western blot analysis. e A375 cells were infected with adenovirus expressing shTGF-β1 at 100
MOI, and after 6 h, infected cells were treated with p38 inhibitor (SB203580, 10 μM) or JNK inhibitor (SP600125, 10 μM) or both for 42 h. Then the
expression of NOX4 and GAPDH was detected by western blot analysis. f A375 cells were infected with adenovirus expressing shTGF-β1 at 100 MOI
or adenovirus expressing shTGF-β1 followed by NAC (10 mM) or adenovirus expressing shTGF-β1 followed by p38 inhibitor (SB203580, 10 μM) or
adenovirus expressing shTGF-β1 followed by transfection with pCMV6-myr-Akt or adenovirus expressing shTGF-β1 followed by transfection with
siRNA of Smad4 based on the siRNA transfection protocol (Santa Cruz, CA, USA). After 48 h, the expression levels of NOX4 mRNA were assayed by
quantitative real-time polymerase chain reaction (qRT-PCR). Error bars represent the standard error from three independent experiments. Asterisks
indicate a significant difference compared to each given control (*p < 0.05; **p < 0.01). g A375 cells were infected with adenovirus expressing shTGF-
β1 at 100 MOI or adenovirus expressing shTGF-β1 followed by transfection with siRNA of Smad4. After 48 h, NOX4 and GAPDH were detected by
western blot analysis. h A375 cells were infected with adenovirus expressing shTGF-β1 at 100 MOI or adenovirus expressing shTGF-β1 followed by
transfection with siRNA of NOX4 based on the siRNA transfection protocol (Santa Cruz, CA, USA). After 48 h, cell viability was tested via an MTS
viability assay (upper left), or cells were incubated with DCF-DA (20 μM, 1 h) for the detection of ROS using a fluorescent reader and microscopy
(upper right, lower left) or the expression levels of various ER stress markers; in addition, PARP, p-ASK1, ASK1, p-p38, p38, p-JNK, and JNK were
detected by western blot analysis (right). i A375 cells were infected with adenovirus expressing shTGF-β1 at 100 MOI or adenovirus expressing shTGF-
β1 followed by treatment with NOX4 inhibitor (GKT137831, 140 nM). After 48 h, cell viability was tested via an MTS viability assay (upper left), or cells
were incubated with DCF-DA (20 μM, 1 h) for the detection of ROS using a fluorescent reader and microscopy (upper right, lower left) or the
expression levels of various ER stress markers; in addition, PARP, p-ASK1, ASK1, p-p38, p38, p-JNK, and JNK were detected by western blot analysis
(right). j A375 cells were infected with adenovirus expressing shTGF-β1 at 100 MOI or adenovirus expressing shTGF-β1 followed by transfection with
siRNA of NOX4 or NOX1 based on the siRNA transfection protocol (Santa Cruz, CA, USA). After 48 h, cell viability was tested via an MTS viability assay
(upper left), or cells were incubated with DCF-DA (20 μM, 1 h) for the detection of ROS using a fluorescent reader and microscopy (upper right, lower
left) or the expression levels of various ER stress markers; in addition, PARP, p-ASK1, ASK1, p-p38, p38, p-JNK, and JNK were detected by western blot
analysis (right)
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localization in the nucleus was reduced, as observed by
confocal immunofluorescence staining (Fig. 5e), and the
reduced amount of Smad4 in the nucleus during TGF-β
downregulation was further confirmed by nucleus/cytosol
fractionation (Fig. 5f). Smad4 downregulation confirmed
that Smad4 is a key mediator of TGF-β downregulation-
induced Trx and GSTM1 suppression (Fig. 5g). However,
intriguingly, NAC treatment did not recover the original
state of phosphorylated Smad2, Smad3, or GSTM1/Trx
prior to TGF-β downregulation (Fig. 5h, i). These data
suggest that the reduced expression of Trx and GSTM1
results from decreased levels of their transcriptional
binding proteins, such as AP-1 and Sp1 and their sub-
sequent reduced interactions with Smad proteins rather
than from ROS generation.
phospho-JNK/phospho-p38 functions as a bridge from
ROS to the ASK1 axis in a positive feedback activation loop
To investigate the possibility of ROS-mediated ER stress
in TGF-β downregulation, various ER stress-related
molecules were examined. Higher expression levels of
ER stress markers (CHOP, PDI, and Ero1-Lα) and
increased phosphorylation of ER stress regulators (IRE1α
and phospho-PERK) were observed (Fig. 6a, left). The
increase in ER markers was reduced by repression of ROS
by NAC (Fig. 6a, right), and p38/JNK inhibition sig-
nificantly recovered cell viability (Fig. 6b) with a con-
current decrease in ER stress-related molecules and ROS
production (Fig. 6c, d). Moreover, similar events also
occurred in cells after p38/JNK inhibition: a decrease in
ASK1-Trx/GSTM1 dissociation (Fig. 6e) along with a
decrease in PARP cleavage (Fig. 6f). Taken together, these
results suggest that p-p38/p-JNK and ROS cooperatively
enhanced TGF-β downregulation-induced cell death
through persistent ER stress in A375 cells with NOX4
expression.
Adenovirus expressing TGF-β shRNA increases tumor
regression in a mouse model
To examine the in vivo potential of TGF-β shRNA-
expressing adenoviruses, we treated nude mice with A375
or HPAC cell grafts. After confirming TGF-β down-
regulation following treatment with a replication-
incompetent adenovirus expressing TGF-β shRNA,
replication-incompetent adenoviruses (expressing TGF-
β1 or scrambled shRNA as an NC) were tested in nude
mice for suppression of tumor growth compared to PBS.
Tumor suppression in both cells increased in the order of
Ad-shTGF-β1 > Ad-NC > PBS (Fig. 7a, upper). Likewise,
the survival rate increased in the order of Ad-shTGF-β1 >
Ad-NC > PBS (Fig. 7a, bottom). The expression levels of
adenovirus estimated by Hexon staining and TGF-β1 in
tumor tissue after infection were as expected, as deter-
mined by immunostaining (Fig. 7b). Apoptosis and
necrotic events were also increased by an adenovirus
containing TGF-β shRNA (Fig. 7c).
In summary, downregulation of TGF-β induces cancer
cell death via the ASK1–SAPK axis signaling cascade.
(see figure on previous page)
Fig. 3 ASK1 functions as a key mediator of TGF-β downregulation-induced cell death triggered by non-canonical signaling Akt
inactivation a ASK1 mediates TGF-β-induced cell death via p38/JNK activation. A375 and HPAC cells were infected with adenovirus expressing
shTGF-β1 or -β2 (100 MOI) and subsequently transfected with siASK1. siASK1 transfection was based on the siRNA transfection protocol (Santa Cruz,
CA, USA). After 48 h, cell viability was tested by an MTS viability assay. Error bars represent the standard error from three independent experiments.
Asterisks indicate a significant difference compared to each given control (*p < 0.05; **p < 0.01). b A375 and HPAC cells were infected with
adenovirus expressing shTGF-β1 or -β2 and subsequently transfected with siASK1. After 48 h, morphological changes were observed using
microscopy. c A375 and HPAC cells were infected with adenovirus expressing shTGF-β1 or -β2 and subsequently transfected with siASK1. After 48 h,
the expression levels of p-p38, p-Akt, p-HSP27, HSP27, p-ERK, p-src, p-p65, p-JNK, p-stat3, and GAPDH were detected by western blot analysis. d A375
and HPAC cells were infected with adenovirus expressing shTGF-β1 or -β2 and subsequently transfected with ASK1 kinase mutant ASK1 (K709M).
After 48 h, cell viability was tested with an MTS viability assay. Error bars represent the standard error from three independent experiments. Asterisks
indicate a significant difference compared to each given control (*p < 0.05; **p < 0.01). e A375 and HPAC cells were infected with adenovirus
expressing shTGF-β1 or -β2 and subsequently transfected with ASK1 kinase mutant ASK1 (K709M). After 48 h, morphological changes were observed
using microscopy. f A375 and HPAC cells were infected with adenovirus expressing shTGF-β1 or -β2 and subsequently transfected with ASK1 kinase
mutant ASK1 (K709M). After 48 h, the expression levels of p-p38, p-Akt, p-HSP27, HSP27, p-ERK, p-src, p-p65, p-JNK, p-stat3, and GAPDH were detected
by western blot analysis. g A375 cells were infected with adenovirus expressing shTGF-β1 and subsequently transfected with siSmad4. After 48 h of
incubation with DCF-DA (20 μM, 1 h), ROS were detected using a fluorescent reader and microscopy. h After 48 h, the expression of various ER stress
markers in addition to survival-related molecules was detected by western blot analysis; A375 cells were infected with adenovirus expressing shTGF-
β1 and subsequently transfected with pCMV6-myr-Akt. i After 48 h of incubation with DCF-DA (20 μM, 1 h), ROS were detected using a fluorescent
reader and microscopy. j After 48 h, the expression levels of various ER stress markers and phospho-Akt and Akt were detected by western blot
analysis. k After 48 h, the expression levels of PARP, p-ASK1, ASK1, p-p38, p38, p-JNK, JNK, and GAPDH were detected by western blot analysis. l After
48 h, cell viability was tested via an MTS viability assay. Error bars represent the standard error from three independent experiments. Decreased p
value to 0.041 from <0.001 after Akt activation followed by TGF-β1 downregulation means a significant decrease in cell death
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Figure 7d provides a schematic diagram summarizing the
results.
Discussion
The expression of TGF-β isoforms is increased in many
types of cancers. For example, a high level of TGF-β1 has
been detected in gastric cancer55, and levels of TGF-β1
and TGF-β2 are markedly increased in hepatocellular
carcinoma and pancreatic cancer cells56,57. In addition,
high TGF-β levels are associated with resistance to
anticancer treatments58. We found that shRNAs targeting
TGF-β1 or TGF-β2 strongly inhibited the growth and
survival of tumor cells.
We also found that ASK1 activation was induced by
TGF-β downregulation via two separate pathways. One
pathway involved decreased gene expression of ASK1-
inhibitory binding proteins, and the other functioned
through ROS generation and the dissociation of ASK1
protein complexes. Up to the present, Grx and Prx, in
addition to Trx and GSTM1, are also known as redox
sensors59–62. In fact, endogenous cellular Grx levels in
various cancer cells, including A375 and HPAC, were
rarely detected (data not shown), whereas cellular Prx was
detected in higher amounts in A375 cells. However, the
cellular Prx level was not decreased, even after TGF-β1
downregulation, and its interaction with ASK1 was rarely
detected (Suppl. Figure 5). Therefore, we focused on the
explanation of the ASK1–p38/JNK axis after TGF-β
downregulation with Trx and GSTM1. Furthermore, we
found that TGF-β downregulation repressed the tran-
scription of Trx and GSTM1 via Smad signaling. In fact,
in normal cells, Smad-mediated gene responses are not
oncogenic, but in cancer cells, they become mediators of
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Fig. 4 Decreases in Trx and GSTM1 expression and the formation of complexes with ASK1 after TGF-β downregulation. a A375 and HPAC
cells were infected with adenovirus expressing shTGF-β1 or -β2 at 100 MOI, respectively. After 48 h, the expression levels of p-ASK1, ASK1, Trx, GSTM1
and GAPDH were detected by western blot analysis. b A375 and HPAC cells were infected with adenovirus expressing shTGF-β1 or -β2 at 100 MOI,
respectively. After 48 h, the expression levels of Trx and GSTM1 mRNA were assayed by quantitative real-time polymerase chain reaction (qRT-PCR).
Error bars represent the standard error from three independent experiments. Asterisks indicate a significant difference compared to each given
control (*p < 0.05; **p < 0.01). c A375 cells were infected with adenovirus expressing shTGF-β1 or -β2 at 100 MOI. After 48 h, lysates were then
subjected to immunoprecipitation with an anti‐Trx (Left) or anti‐GSTM1 (Right) antibody to identify changes in complex formation. The numbers
indicate the relative band intensity to that of Ad-NC. d A375 cells were infected with adenovirus expressing shTGF-β1 or -β2 at 100 MOI. After 6 h,
infected cells were treated with NAC (10mM) for 42 h. Then lysates were subjected to immunoprecipitation with an anti‐Trx (Left) or anti‐GSTM1
(Right) antibody to identify changes in complex formation. The numbers indicate the relative band intensity to that of Ad-NC after measuring band
intensity using a densitometer
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Fig. 5 Regulation of Trx and GSTM1 promoter activity by TGF-β downregulation via a Smad complex. a A375 and HPAC cell lines were
infected with adenovirus expressing shTGF-β1 or -β2 at 100 MOI, respectively. After 48 h, Trx and GSTM1 promoter activities were analyzed by Chip
assays using antibodies to AP-1 or Sp1. Error bars represent the standard error from three independent experiments. Asterisks indicate a significant
difference compared to each given control (*p < 0.05; **p < 0.01). b A375 and HPAC cells were infected with adenovirus expressing shTGF-β1 or -β2
at 100 MOI, respectively. After 48 h, the expression levels of AP-1, Sp1 and GAPDH were detected by western blot analysis using whole-cell lysates. c
p-Smad2, Smad2, p-Smad3, Smad3, Smad4, and GAPDH were detected by western blot analysis. d A375 cells were infected with adenovirus
expressing shTGF-β1 or -β2 at 100 MOI. After 48 h, lysates were then subjected to immunoprecipitation with an anti‐AP1 or anti-Sp1 antibody to
identify changes in Smad4 in complex formation. e A375 cells were infected with adenovirus expressing shTGF-β1 or -β2 at 100 MOI. After 48 h,
Smad4 localization was examined by confocal immunofluorescence staining. Representative confocal immunofluorescence staining of each infected
A375 was performed as described in the Materials and methods section to confirm the localization of Smad4. f A375 and HPAC cells were infected
with adenovirus expressing shTGF-β1 or -β2 at 100 MOI, respectively. After 48 h, Smad4 localization was examined in nuclear or cytosolic
fractionation using nuclear (histone 1) or cytosol (actin) markers. g A375 and HPAC cell lines were transfected with negative control siRNA or
Smad4 siRNA. After 48 h, transfected cells were detected with GSTM1, Trx, Smad4, and GAPDH. h Effects of NAC on Trx and GSTM1 expression in
melanoma and pancreatic cancer cells expressing shTGF-β1 or -β2 adenovirus. A375 and HPAC cells were infected with adenovirus expressing shTGF-
β1 or -β2 at 100 MOI, respectively. After 6 h, infected cells were treated with NAC (10 mM) for 42 h. Then, p-Smad2, p-Smad3, Trx, GSTM1, and GAPDH
were detected by western blot analysis. i A375 and HPAC cells were infected with adenovirus expressing shTGF-β1 or -β2 at 100 MOI, respectively.
After 6 h, infected cells were treated with NAC (10 mM) for 42 h. Then the expression levels of Trx and GSTM1 mRNA were assayed by quantitative
real-time polymerase chain reaction (qRT-PCR). Error bars represent the standard error from three independent experiments. Asterisks indicate a
significant difference compared to each given control (*p < 0.05; **p < 0.01)
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cells retain functional Smad signaling, the cellular context
might determine whether this pathway promotes cancer,
as demonstrated by TGF-β signaling11.
In the context of physiological/pathophysiological set-
tings, SAPKs are of vital importance to the life or death of
a cell63. Their effects are determined by the precise nature
of the extracellular stimuli and the repertoire of molecules
available in the cell, which regulate the localization, tim-
ing, intensity, and duration of SAPK activation64. Owing
to this complexity, the molecular understanding of how
JNK and p38 SAPK family members function as either
tumor suppressors or oncoproteins in specific cell types
remains unknown65. There are some reports that JNK and
p38 have completely different functions depending on the
duration of activation; transient JNK and p38 induction
provides a survival signal, whereas persistent activation
induces apoptosis29,66. In this study, we found that p38
activation (induced by TGF-β downregulation) was par-
ticularly related to cancer cell death rather than cell sur-
vival due to both the sustained duration and strong
Fig. 6 Involvement of reciprocal ER stress and SAPK activation during TGF-β downregulation-induced cell death. a A375 cells were infected
with adenovirus expressing shTGF-β1 or -β2. After 48 h, various ER stress-related proteins were detected by western blot analysis. b A375 cells were
infected with adenovirus expressing shTGF-β1 at 100 MOI, and after 6 h, infected cells were treated with a JNK inhibitor (SP600125, 10 μM) or a p38
inhibitor (SB203580, 10 μM) for 42 h. Then cell viability was tested using an MTS viability assay (left). Error bars represent the standard error from three
independent experiments. Asterisks indicate a significant difference compared to each given control (**p < 0.01). Additionally, the expression levels of
PARP and GAPDH were detected by western blot analysis (right). c A375 cells were infected with adenovirus expressing shTGF-β1 at 100 MOI, and
after 6 h, infected cells were treated with a JNK inhibitor (SP600125, 10 μM) or a p38 inhibitor (SB203580, 10 μM) for 42 h. Then ER stress-related
proteins that responded to TGF-β downregulation (Fig. 5a) were detected by western blot analysis. d A375 cells were infected with adenovirus
expressing shTGF-β1 at 100 MOI, and after 6 h, infected cells were treated with a JNK inhibitor (SP600125, 10 μM) or a p38 inhibitor (SB203580, 10 μM)
for 42 h and then incubated with DCF-DA (20 μM, 1 h) for the detection of ROS using a fluorescent reader and microscopy. e A375 cell lines were
infected with adenovirus expressing shTGF-β1 at 100 MOI, and after 6 h, infected cells were treated with a JNK inhibitor (SP600125, 10 μM) or a p38
inhibitor (SB203580, 10 μM) for 42 h. Then lysates were subjected to immunoprecipitation using an anti-Trx or anti-GSTM1 antibody to identify
changes in ASK1. f A375 cells were infected with adenovirus expressing shTGF-β1 at 100 MOI, and after 6 h, infected cells were treated with a JNK
inhibitor (SP600125, 10 μM) or a p38 inhibitor (SB203580, 10 μM) for 42 h. Then the expression levels of PARP, ASK1, p-ASK1, p-p38, p38, p-JNK, JNK,
Trx, GSTM1, and GAPDH were detected by western blot analysis
Han et al. Experimental & Molecular Medicine          (2018) 50:162 Page 15 of 19




















































































Fig. 7 (See legend on next page.)
Han et al. Experimental & Molecular Medicine          (2018) 50:162 Page 16 of 19
Official journal of the Korean Society for Biochemistry and Molecular Biology
intensity of activation. p38 mitogen-activated protein
kinase was first known to be activated in response to
TGF-β treatment but not to TGF-β downregulation67–70.
In this case, TGF-β suppressed growth in normal epi-
thelial cells, thereby acting in a cytostatic role to prevent
the generation of hyperproliferative disorders such as
cancer1. However, with an accumulation of genetic and
epigenetic alterations in tumor cells, its function switches
to the promotion of a pro-invasive and pro-metastatic
phenotype, accompanied by a progressive increase in
locally secreted TGF-β levels1. Owing to the dichotomous
nature of TGF-β acting as both a tumor suppressor and a
significant stimulator of tumor progression, depending on
the cell types in which it is activated, TGF-β treatment or
TGF-β downregulation can be used to induce normal cell
death or cancer cell death, respectively, of the epithelium
through the same signaling pathway. In contrast to TGF-β
downregulation in cancer cells, even excessive TGF-β
treatment in the same cancer cells did not show any
cancer cell death. Instead, TGF-β downregulation was
accompanied by weak activation of p38 and a few anti-
apoptotic molecules, reflecting a low sensitivity of cancer
cells with higher levels of TGF-β to TGF-β treatment and
again verifying a role of TGF-β as a regulator of cancer
cell progression58,71. Our results indicating that the dif-
ferential p38 activation of TGF-β downregulation and
TGF-β treatment is correlated with cellular destination
are also similar to our previous reports that a biphasic role
exists depending on the activation level of p38, that is, cell
death with strong p38 activation or cell survival with weak
p38 activation after treatment with anticancer agents,
such as curcumin or tumor necrosis factor-related apop-
tosis-inducing ligand72,73.
Interestingly, TAK1, which is known to be activated by
TGF-β family ligands23 and is thought to be a survival
signal, did not contribute to the effects observed in this
study (data not shown). Rather, we identified ASK1-
induced JNK/p-38 as the primary apoptosis signal origi-
nating from TGF-β downregulation-induced Akt inacti-
vation. However, it is still difficult to determine whether
ASK1–p38/JNK is the only specific key signaling molecule
in the SAPK pathway.
Another finding from this study was that the down-
regulation of TGF-β in cancer cells could promote ROS
generation depending on the cancer cell type. TGF-β1
downregulation in A375 cells enhanced ROS in a NOX4-
dependent manner, whereas TGF-β2 downregulation in
A375 cells or TGF-β1 or -β2 downregulation in HPAC
seemed to generate few ROS in a non-NOX4-dependent
manner. The increase in ROS in A375 cells after TGF-β1
downregulation was likely triggered by a decrease in
tumor-promoting non-canonical Akt activation25,74
mediated by NOX4 expression rather than by the cano-
nical Smad signaling pathway, which is also known to
have a tumor-promoting role75. The cellular redox state is
determined by ROS production and elimination under
different conditions. (A) Under normal conditions, cancer
cells maintain redox homeostasis by balancing ROS pro-
duction and elimination. (B) Under metabolic stress,
redox homeostasis is damaged owing to enhanced ROS
production and decreased ROS elimination76. Based on
these two possible environments, lower levels of ROS can
oxidize the disulfide bridges in Akt, leading to the asso-
ciation of Akt with PP2A and thus short-term activation
of Akt77. However, because higher levels of ROS corre-
spond to an overall decrease in cell survival potential,
including Akt inactivation, resulting in severe damage to
survival–death homeostasis, ROS are likely to be an
irreversible sign of cell death, exacerbating ASK1-induced
cell death through enhanced ER stress conditions.
Taken together, our findings demonstrated that the
downregulation of TGF-β via shRNAs induced tumor cell
(see figure on previous page)
Fig. 7 Antitumor effect and schematic diagram of cancer cell death by TGF-β downregulation. a BALB/c athymic nude mice were injected
with 8 × 106 A375 or HPAC cells in 100 μL. When the tumors reached an average size of 60–80 mm3, the nude mice received intratumoral injections
of 1 × 109 plaque-forming units (pfu) of various kinds of adenovirus (Ad-NC, Ad-shTGF-β1, or Ad-shTGF-β2) in 50 μL of PBS or PBS alone on days 1, 3,
and 5. Tumor volume was monitored and recorded every 2 days until the end of the study. Values represent the mean ± SE (five animals per group)
(top). Asterisks indicate a significant difference compared to each given control (*p < 0.05; **p < 0.01). Overall survival was determined throughout a
31-day time course (bottom). b Representative immunohistochemical analysis of recombinant adenovirus-infected tumor sections was performed as
follows. Three animals per group of BALB/c athymic nude mice were injected with 8 × 106 A375 or HPAC cells/100 μL and treated with intratumoral
injections of 1 × 109 pfu/50 μL of various types of adenovirus (Ad-NC, Ad-shTGF-β1, or Ad-shTGF-β2) on days 1, 3, and 5. Tumors were collected on
day 11 for histological analysis. Paraffin sections of tumor tissue were stained using anti-Hexon, anti-TGF-β1, and anti-TGF-β2 antibodies. c A TUNEL
assay was performed on tissue sections to quantify apoptotic cell death, as described in the “Materials and methods” section. The percentage of
TUNEL-positive cells was determined by counting the TUNEL-positive cells under 10 noncontinuous low-power fields. d TGF-β1 or -β2
downregulation can cause both NOX4-mediated ROS production and a reduction in Smad complexes (phospho-Smad2, 3 with Smad4) that
translocate to the nucleus to bind to gene promoters for the expression of Trx/GSTM1. ROS triggered by decreased Akt activity can dissociate Trx or
GSTM1 from ASK1–Trx and ASK1-GSTM1 complexes. ASK1 activation is also related to the reduction in Trx and GSTM1 gene expression, which results
from decreased transcriptional activity of the Smad complex. In these ways, ASK1 was fully activated and induced cytotoxic tumor cell death via p38/
JNK activation and induction of ER stress, which stimulated the escalation of ASK1 activation by completion of a sustained positive feedback loop
circuit. Circled numbers indicate the chronological order of the signaling events leading to escalated cancer cell death
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death, an effect that was driven by ASK1–SAPK axis
signaling cascade regulated by a positive feedback circuit
triggered by Akt inactivation/NOX4 increase-derived
ROS-mediated ER stress (A375 cells) or tumor cell
death driven by direct ASK1–SAPK axis signaling cascade
(HPAC cells). For the goal of cancer treatment, it would
be desirable to retain the TGF-β-mediated stimulation of
apoptosis in tumor cells but inhibit the cell-autonomous
and non-cell-autonomous activities of TGF-β8. In light of
this viewpoint, downregulation of TGF-β rather than
knockout might result in a more effective therapeutic
regimen. However, it is challenging to predict whether the
blockade of TGF-β with inhibitors would be sufficient to
block the tumor-promoting effects of TGF-β without
affecting its tumor-suppressive functions78. Nevertheless,
our data provide an underlying mechanism of how TGF-β
downregulation induces cancer cell death.
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